20%涨停！688189爆猛料，机构提前杀入

Core Viewpoint - Nanjing New Pharmaceutical has experienced a significant stock price increase following the announcement of plans to acquire a domestic pharmaceutical technology asset group, although it remains uncertain if this constitutes a major asset restructuring [2][18]. Stock Performance - On July 29 and 30, Nanjing New Pharmaceutical's stock price surged, reaching a closing price of 14.28 yuan per share, marking a 20% increase and a total market capitalization of 3.918 billion yuan [4][12]. - The stock's price deviation over three trading days from July 28 to July 30 reached a cumulative increase of 30%, qualifying as an abnormal trading fluctuation under Shanghai Stock Exchange regulations [8][18]. - On July 29, the stock saw a late surge, closing with a 17.01% increase, while on July 30, it hit the daily limit with a 20% increase [10][12]. Institutional Investment - During the price surge, Nanjing New Pharmaceutical appeared on the "Dragon and Tiger List," indicating significant buying activity from institutional accounts, with the top five buying and selling accounts being institutional [7][15]. Financial Performance - Nanjing New Pharmaceutical has faced declining financial performance, with net profits for the years 2022 to 2024 reported as -78.83 million yuan, -10.87 million yuan, and -357 million yuan respectively, indicating a trend of increasing losses [18][20]. - In the first quarter of 2025, the company reported a year-on-year decline in operating revenue, net profit attributable to shareholders, and net profit after deducting non-recurring gains and losses of 70.21%, 143.66%, and 146.27% respectively [20].